A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial.
This was a phase II investigation of high-dose imatinib in 15 adult patients with relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia (AML). Imatinib 600 mg daily was administered for 1 month followed by dose escalation to 800 mg daily for a maximum of 2 months. No clinical responses were reported with early death due to disease progression reported in 7 patients. While no activity was seen in this phase II trial, the findings of the study do not rule out efficacy in subsets of AML with imatinib-sensitive Kit mutations.
Chevallier
Patrice
P
Service d'Hématologie Clinique, CHU Hotel-Dieu, Nantes, France. patrice.chevallier@chu-nantes.fr
Hunault-Berger
Mathilde
M
Larosa
Fabrice
F
Dauriac
Charles
C
Garand
Richard
R
Harousseau
Jean-Luc
JL
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D018572:Disease-Free Survival; D005260:Female; D016313:Genes, abl; D006801:Humans; D000068877:Imatinib Mesylate; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D019009:Proto-Oncogene Proteins c-kit; D011743:Pyrimidines / Q000008:administration & dosage*; D015996:Survival Rate; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit